180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company is headquartered in Palo Alto, California. The company went IPO on 2017-06-07. The firm is focused on iGaming sector, through its iGaming Technology Platform. The firm also continues to evaluate monetization strategies for its biotechnology assets.
最新の財務諸表(Form-10K)によると、180 Life Sciences Corpの総資産は$41で、純損失は$0です。
ATNFの主要な財務比率は何ですか?
180 Life Sciences Corpの流動比率は5.85、純利益率は0、1株当たり売上高は$4.21です。
180 Life Sciences Corpの収益はセグメントまたは地域別にどのように分けられていますか?
180 Life Sciences Corp の最大収益セグメントは Testing Services で、最新の利益発表における収益は 17,933,000 です。地域別に見ると、Singapore and Asia が 180 Life Sciences Corp の主要市場であり、収益は 42,287,000 です。